Swiss Pharma Nigeria Limited (SWIPHA), a subsidiary of Servier, a French multinational pharmaceutical company, has received WHO pre-qualification of Zinc Dispersible 20mg Tablet from the World Health Organization (WHO).
SWIPHA is the first company in Africa to obtain WHO prequalification for Zinc Tablet.
The WHO pre-qualification a rigorous process that evaluates pharmaceutical products based on their quality, safety, and efficacy. It is considered worldwide as a symbol of excellence in pharmaceutical manufacturing.
“We are thrilled to announce to the public that we have received World Health Organization pre-qualification of Zinc Dispersible 20mg Tablet on May 2, 2023. As many may know, our company has been dedicated to providing high-quality pharmaceutical products that meet the highest safety and efficacy standards for over 47 years,” Frederic Lieutaud, the managing director of Swiss Pharma Nigeria Limited, said in a statement on Sunday.
The WHO pre-qualification, Lieutaud added, “validates the dedication and hard work of our entire team, who have worked tirelessly to ensure that our products meet the highest standards of quality and safety. It is also evidence of our commitment to transparency and accountability in everything we do.”
He said the company could only have achieved the feat with the support of its partners and clients. “We want to convey our most profound appreciation to some of our partners, regulatory bodies and customers, including the United States Agency for International Development (USAID), National Agency for Food and Drug Administration and Control (NAFDAC), World Health Organization (WHO) Nigeria, Servier Generic Group, the United States Pharmacopoeia – Promoting the Quality of Medicines
Plus (USP-PQM+), Maternal and Child Centre, Amuwo Odofin, Lagos, the General Hospital Alimosho, Lagos, Adeoyo Maternity Teaching Hospital, Ibadan and all other stakeholders who supported our journey to prequalification,” he said.